{"id":5735,"date":"2019-08-13T14:32:15","date_gmt":"2019-08-13T09:02:15","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5735"},"modified":"2021-07-24T12:57:29","modified_gmt":"2021-07-24T07:27:29","slug":"pharma-happenings-for-ascletis-cavion-jazz-pharma-gna","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna","title":{"rendered":"GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn; Jazz Pharmaceuticals acquires Cavion; Ascletis opens a new Shanghai clinical research centre"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fb94b06835d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fb94b06835d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna\/#GNA_Biosolutions_nets_USD_135_Million_in_a_Series_C_Funding\" >GNA Biosolutions nets\nUSD 13.5 Million in a Series C Funding<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna\/#AC_Immune_forms_a_Research_Collaboration_with_Penn_to_accelerate_Neurodegenerative_Diseases_Pipeline\" >AC Immune forms a Research Collaboration with Penn to accelerate Neurodegenerative Diseases Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna\/#Jazz_Pharmaceuticals_Announces_Acquisition_of_Cavion_for_USD_312_Million\" >Jazz Pharmaceuticals Announces Acquisition of Cavion for USD 312\nMillion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna\/#Ascletis_opens_a_new_Clinical_Development_Centre_in_Shanghai\" >Ascletis opens a new Clinical Development Centre in Shanghai<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"GNA_Biosolutions_nets_USD_135_Million_in_a_Series_C_Funding\"><\/span><strong>GNA Biosolutions nets\nUSD 13.5 Million in a Series C Funding <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>GNA Biosolutions<\/strong> has secured USD 13.5 Million completing its all the rounds of financing. GNA Biosolutions GmbH, a Germany-based molecular diagnostics company has been able to successfully secure IVD-CE marking of its first point-of-care (POC) molecular diagnostic platform based on its Pulse Controlled Amplification (PCA) technology. The Series C round was joined by <strong>GNA\u2019s previous investors<\/strong>, <strong>SHS Gesellschaft f\u00fcr Beteiligungsmanagement<\/strong>, <strong>Robert Bosch Venture Capital<\/strong>, <strong>UVC Partners, Mey Capital Matrix<\/strong>, <strong>KfW <\/strong>and <strong>btov Partners<\/strong>. New investors <strong>GreyBird Ventures<\/strong>, <strong>Occident<\/strong>, and <strong>Wachstumsfonds<\/strong> <strong>Bayern <\/strong>also participated in the round.<br>The company plans to use the proceedings to produce portable, battery-operated devices\u2014along with infectious disease assays for tuberculosis, MRSA and drug-resistant Gram-negative bacteria within a minute. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AC_Immune_forms_a_Research_Collaboration_with_Penn_to_accelerate_Neurodegenerative_Diseases_Pipeline\"><\/span><strong>AC Immune forms a Research Collaboration with Penn to accelerate Neurodegenerative Diseases Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Swiss-based, <strong>AC Immune <\/strong>SA, a clinical-stage Biopharmaceutical Company today broadcasted a research partnership with researchers and scientists in the Perelman School of Medicine at the University of Pennsylvania (Penn). The collaboration is focused on reviewing and exploring the pathological mechanisms of <strong>TDP-43<\/strong> misfolding and accumulation and to develop novel therapeutic and diagnostic approaches against FTLD and other <strong>neurodegenerative diseases.<\/strong><br>TDP-43 is a transcriptional repressor DNA binding protein and represses HIV-1 transcription. In addition, this protein regulates alternate splicing of the CFTR gene. The research will exclusively revolve around pathological forms of TDP-43 in a neuron, for a better understanding of the TDP-43 pathologies. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Jazz_Pharmaceuticals_Announces_Acquisition_of_Cavion_for_USD_312_Million\"><\/span><strong>Jazz Pharmaceuticals Announces Acquisition of Cavion for USD 312\nMillion <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Jazz Pharmaceuticals<\/strong>, a global biopharmaceutical company, acquires Cavion through a merger with a Jazz subsidiary. Under the agreement, Cavion is eligible to receive an upfront payment of USD 52.5 Million and an additional amount of USD 260 Million on successful completion of clinical trials and commercial milestones. <strong>CX-8998<\/strong>, a lead molecule, under Phase II evaluation in patients suffering from tremors. <br><strong>Cavion<\/strong>, now a wholly-owned subsidiary of Jazz, develops therapies which modulate the T-type calcium channel for the treatment of chronic and rare neurological diseases.&nbsp; CX-8998, a lead molecule, under Phase II evaluation, placebo-controlled clinical study in patients with essential tremor. The study confirmed the continued development of CX-8998 as a potential treatment for essential tremor.&nbsp; <br>The acquisition of Cavion backs up the Jazz\u2019s to further expand its pipeline and product portfolio to help improve the healthcare standards. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ascletis_opens_a_new_Clinical_Development_Centre_in_Shanghai\"><\/span><strong>Ascletis opens a new Clinical Development Centre in Shanghai <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Ascletis Pharma, a commercial-stage biotechnology company has inaugurated a new clinical development centre at the heart of Shanghai, located at Jing&#8217;an Kerry Centre near Nanjing West Road. The idea behind opening a new centre in Shanghai was to use its strategic location to attract new talent. <br>An innovative R&amp;D driven company is dedicated to address unmet medical needs in the field of anti-viral, cancer and fatty liver diseases. This further will help in the expansion of R&amp;D capability, especially in Oncology and Non-alcoholic steatohepatitis (<a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market\">NASH<\/a>).<br>Currently, there is no approved therapy for the NASH treatment, yet doctors prescribe certain off-label drugs (supportive therapies) for its management. DelveInsight estimates that the <a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-epidemiology-forecast\">Nonalcoholic Steatohepatitis market<\/a> likely to experience significant annual growth over the 2017\u20132028 study period, as major-market sales are expected to increase by 2028. Several key pharma players including Genfit, Intercept Pharmaceuticals, Gilead Sciences, Allergan (Tobira Therapeutics), Bristol-Myers Squibb, Cirius Therapeutics, Conatus Pharmaceuticals, Galectin Therapeutics, and many others are involved in advancing the <a href=\"https:\/\/www.delveinsight.com\/blog\/nash-upcoming-drugs\/\">NASH therapy<\/a> market.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GNA Biosolutions nets USD 13.5 Million in a Series C Funding GNA Biosolutions has secured USD 13.5 Million completing its all the rounds of financing. GNA Biosolutions GmbH, a Germany-based molecular diagnostics company has been able to successfully secure IVD-CE marking of its first point-of-care (POC) molecular diagnostic platform based on its Pulse Controlled Amplification [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5738,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17751,107,1271,17505,349,639],"industry":[17225],"therapeutic_areas":[17239,17245],"class_list":["post-5735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ascletis","tag-bayer","tag-delveinsight-pharma-news","tag-jazz-pharmaceuticals","tag-latest-pharma-news","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn<\/title>\n<meta name=\"description\" content=\"the Nonalcoholic Steatohepatitis market likely to experience significant annual growth. Several key pharma players... the NASH therapy market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn\" \/>\n<meta property=\"og:description\" content=\"the Nonalcoholic Steatohepatitis market likely to experience significant annual growth. Several key pharma players... the NASH therapy market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-08-13T09:02:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180950\/pharma-news-13.8.2019-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn","description":"the Nonalcoholic Steatohepatitis market likely to experience significant annual growth. Several key pharma players... the NASH therapy market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna","og_locale":"en_US","og_type":"article","og_title":"GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn","og_description":"the Nonalcoholic Steatohepatitis market likely to experience significant annual growth. Several key pharma players... the NASH therapy market.","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-08-13T09:02:15+00:00","article_modified_time":"2021-07-24T07:27:29+00:00","og_image":[{"width":750,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180950\/pharma-news-13.8.2019-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna","name":"GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180950\/pharma-news-13.8.2019-1.jpg","datePublished":"2019-08-13T09:02:15+00:00","dateModified":"2021-07-24T07:27:29+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"the Nonalcoholic Steatohepatitis market likely to experience significant annual growth. Several key pharma players... the NASH therapy market.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ascletis-cavion-jazz-pharma-gna#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180950\/pharma-news-13.8.2019-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180950\/pharma-news-13.8.2019-1.jpg","width":750,"height":410,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/08\/09180950\/pharma-news-13.8.2019-1-300x164.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ascletis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">delveinsight pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Jazz Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Ascletis<\/span>","<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">delveinsight pharma news<\/span>","<span class=\"advgb-post-tax-term\">Jazz Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 13, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 13, 2019 2:32 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5735"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5735\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5738"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5735"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5735"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}